Therefore the selective inhibition of RyR2 by the C-terminal half of GSTM2 (GSTM2C) has significant clinical potential in the treatment of inherited and acquired RyR Ca2+-handling based arrhythmia where RyR2 channels are abnormally active, inducing arrhythmias and reducing Ca2+ store filling during diastole and contractility. This evidence concerns the gene GSTM2 and cardiac arrhythmia.